Prev   Next       Pause   Play    



Be Empowered Webinar:
The Promise and Peril of Panel Genetic Testing for Inherited Cancer Susceptibility

Sponsored by FORCE  
(Facing Our Risk of Cancer Empowered)
Tuesday, March 24th at 12 PM EST

Panel genetic testing for inherited cancer risk looks for mutations in a number of different genes.  What information can you get from a panel test and how can it help you make decisions about managing cancer risk?  Join Licensed Genetic Counselor Jill Stopfer, MS, CGC of the University of Pennsylvania's Basser Research for BRCA as she discusses the use of panel testing in cancer risk assessment.



The Foundation for Women's Cancer is sponsoring a free Telephone Education Workshop on Advanced Ovarian Canceron Friday, April 17, from 1:00 pm - 2:00 pm Eastern Daylight Time. 

Click here to register!

The workshop is scheduled as follows:
1:00 p.m. - 1:05 p.m.             
Welcome and Overview

1:05 -1:25 pm                              
PARP Inhibitors and Recurrent Ovarian Cancer
Sharyn N. Lewin, MD, Director, Division of Gynecologic Oncology, Regional Cancer Center,
Holy Name Medical Center, Teaneck, NJ

1:25 -1:45 pm                                
Recurrent Ovarian Cancer: When to Re-Operate
John C. Elkas, MD, JD, Mid Atlantic Gynecologic Oncology & Pelvic Surgery, Annandale, VA

1:45 - 2:00 pm                              
Questions and Answers

A Radioshow for Cancer Patients

Listen to "Frankly Speaking About Cancer" every Tuesday at 4pm eastern time (1pm pacific time). The host is Kim Thiboldeaux, President and CEO of the Cancer Support Community, stives to empower her listeners to live well with cancer. Click here to visit the website. You can also find past episodes available for listening!


Tribute to Frances Stolusky


Our friend and colleague, Fran Stolusky, passed away on November 4, 2014.  Fran will always be remembered as an active and long-term member of the board of Rhonda’s Club and as the long-time manager of our Survivors Teaching Students classes.  She trained, scheduled and mentored scores of women to share their stories of survival with medical students with the goal of increasing awareness and early detection.  Every year, she helped bring that message to more than 400 students.  Fran also participated in countless health fairs, fundraising walks, conferences and other outreach programs to further our mission to battle gynecologic cancers by raising public awareness of symptoms, educating survivors and medical professionals, and supporting research to improve quality of life, and find the cures.  Fran was always there, and she always got the job done.

And Coming in June….

Join Rhonda’s Club at the
2nd Annual 5K Walk to Break the Silence on Ovarian Cancer®
hosted by National Ovarian Cancer Coalition,
Frederick MD Chapter

Saturday, June 20, 2015
Baker Park
121 Bentz Street, Frederick, MD

view our calendar of events >


On March 18, the Society of Gynecologic Oncology SGO) reported the following Women's Cancer News.

ChemoFx Improves Ovarian Cancer Outcomes

ChemoFx® provides invaluable information to physicians choosing from 20 equivalent treatment recommendations without prior knowledge of how individual ovarian cancer patients may respond. ChemoFx determines platinum resistance in primary ovarian cancer and demonstrates longer overall survival by 14 months in recurrent ovarian cancer, making it instrumental in improving patient outcomes.

Intraperitoneal chemotherapy in ovarian cancer

Long-term findings from two randomized trials demonstrated that intraperitoneal (IP) chemotherapy significantly improved survival compared with intravenous (IV) therapy. The combined analysis of the GOG-172 and GOG-114 trials showed that patients treated with IP chemotherapy experienced a 16% reduction in the risk of progression compared with IV therapy. Additionally, IP chemotherapy led to a median overall survival (OS) of 62 months compared with 51 months for IV therapy.

Robotic Surgery Report Card

A study found that robotic surgery for benign gynecologic procedures had a higher rate of complication than conventional surgery, and was more costly.

FDA Approves Avastin Plus Chemotherapy to Treat Women With Platinum-Resistant Recurrent Ovarian Cancer


November 14, 2014, the Food and Drug Administration announced the approval of Genentech’s Avastin (bevacizumab) in combination with chemotherapy for women with platinum-resistant recurrent ovarian cancer. The approval was based on the results of a Phase III clinical trial which showed women who received Avastin with chemotherapy had a 62% improvement in progression free survival (disease worsening) as compared to those who received chemotherapy alone.

Bevacizumab Plus Fosbretabulin Improves Progression-Free Survival in Ovarian Cancer Patients

The combination of the antiangiogenesis drug bevacizumab and the vascular-disrupting agent fosbretabulin is superior to bevacizumab alone in the treatment of recurrent ovarian, tubal, and peritoneal cancer, according to an oral presentation made at the biennial meeting of the International Gynecologic Cancer Society. A study found significant improvement in progression-free survival among patients treated with the combination of bevacizumab and fosbretabulin versus bevacizumab alone, with a median improvement of 2.5 months.

Amgen Ovarian Cancer Drug Fails to Improve Overall Survival

Amgen Inc said its experimental ovarian cancer drug did not show statistically significant improvement in overall survival rate in a late-stage trial. Patients given the drug, trebananib, along with a chemotherapy agent paclitaxel, experienced overall survival of 19.3 months, compared with 18.3 months for the placebo group. Analysts said oncologists expect the drug to have little or no benefits in terms of overall survival and FDA approval seems unlikely.

more resources >



Thank you to our supporters!